1 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
2 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
3 Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
4 Urology and Nephrology Center, Department of Urology, Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
5 Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
6 Department of Urology, University Hospital Zürich, Zürich, Switzerland.
7 Department of Urology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
8 IBM Zürich Research Laboratory, Zürich, Switzerland.
9 State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
10 Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
11 Swiss Institute of Bioinformatics, Lausanne, Switzerland.
12 CECAD, University of Cologne, Cologne, Germany.
13 Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Zürich, Switzerland aebersold@imsb.biol.ethz.ch.
14 Faculty of Science, University of Zürich, Zürich, Switzerland.
15 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China guotiannan@westlake.edu.cn.
16 Goethe University Frankfurt, Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany peter.wild@ukffm.de.
17 Frankfurt Institute for Advanced Studies, Frankfurt am Main, Germany.
This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.